Skip to main content

Advertisement

SpringerLink
Log in

Why are kids with lupus at an increased risk of cardiovascular disease?

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Juvenile-onset systemic lupus erythematosus (SLE) is an aggressive multisystem autoimmune disease. Despite improvements in outcomes for adult patients, children with SLE continue to have a lower life expectancy than adults with SLE, with more aggressive disease, a higher incidence of lupus nephritis and there is an emerging awareness of their increased risk of cardiovascular disease (CVD). In this review, we discuss the evidence for an increased risk of CVD in SLE, its pathogenesis, and the clinical approach to its management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, D’Agostino RB, Kuller LH (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415

    Article  CAS  PubMed  Google Scholar 

  2. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH (2009) Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study. Arthritis Rheum 61:1396–1402

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kamphuis S, Silverman ED (2010) Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 6:538–546

    Article  CAS  PubMed  Google Scholar 

  4. Tucker LB, Menon S, Schaller JG, Isenberg DA (1995) Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 34:866–872

    Article  CAS  PubMed  Google Scholar 

  5. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED (2009) Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 36:2539–2546

    Article  PubMed  Google Scholar 

  6. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J, Armon K, Sinha MD, Ioannou Y, Archer N, Bailey K, Davidson J, Baildam EM, Cleary G, McCann LJ, Beresford MW, Juvenile-Onset UK, Systemic Lupus Erythematosus Study Group (2012) Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum 64:2356–2365

    Article  PubMed  Google Scholar 

  7. Amaral B, Murphy G, Ioannou Y, Isenberg DA (2014) A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatology (Oxford) 53:1130–1135

    Article  Google Scholar 

  8. Mina R, Brunner HI (2010) Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin N Am 36:53–80, vii–viii

    Article  Google Scholar 

  9. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME (2004) Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 3:423–453

    Article  PubMed  Google Scholar 

  10. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, Criswell LA, Yelin E (2010) Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res 62:1152–1159

    Article  Google Scholar 

  11. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA (2002) Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61:409–413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:221–225

    Article  CAS  PubMed  Google Scholar 

  13. Björnådal L, Yin L, Granath F, Klareskog L, Ekbom A (2004) Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population-based study 1964–95. J Rheumatol 31:713–719

    PubMed  Google Scholar 

  14. Bernatsky S, Boivin J-F, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal J-L, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557

    Article  CAS  PubMed  Google Scholar 

  15. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338–346

    Article  CAS  PubMed  Google Scholar 

  16. Urowitz MB, Gladman D, Ibanez D, Bae SC, Sanchez-Guerrero J, Gordon C, Clarke A, Bernatsky S, Fortin PR, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Alarcon GS, Merrill JT, Ginzler E, Khamashta M, Nived O, Sturfelt G, Bruce IN, Steinsson K, Manzi S, Ramsey-Goldman R, Dooley MA, Zoma A, Kalunian K, Ramos M, Van Vollenhoven RF, Aranow C, Stoll T, Petri M, Maddison P, Systemic Lupus International Collaborating Clinics (2010) Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res 62:881–887

    Article  CAS  Google Scholar 

  17. Yiu K-H, Wang S, Mok M-Y, Ooi GC, Khong P-L, Mak K-FH, Lam K-F, Lau C-S, Tse H-F (2009) Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol 36:2212–2217

    Article  CAS  PubMed  Google Scholar 

  18. Salmon JE, Roman MJ (2008) Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 121:S3–8

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shang Q, Tam L, Li E, Yip G, Yu C (2008) Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus 17:1096–1102

    Article  CAS  PubMed  Google Scholar 

  20. Colombo BM, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G, Nobili F, Pisciotta L, Bertolini S, Moccetti T, Dentali F, Steidl L, Ciprandi G, Afeltra A, Indiveri F, Puppo F (2009) Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 8:309–315

    Article  CAS  PubMed  Google Scholar 

  21. Plazak W, Gryga K, Dziedzic H, Tomkiewicz-Pajak L, Konieczynska M, Podolec P, Musial J (2011) Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 13:R117

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sherer Y, Zinger H, Shoenfeld Y (2010) Atherosclerosis in systemic lupus erythematosus. Autoimmunity 43:98–102

    Article  CAS  PubMed  Google Scholar 

  23. Narshi CB, Giles IP, Rahman A (2011) The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus 20:5–13

    Article  CAS  PubMed  Google Scholar 

  24. Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski KL, Ilowite NT, von Scheven E, Eberhard A, Levy DM, Kimura Y, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung LK, Imundo L, Soep JB, Reed AM, APPLE investigators (2010) Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. Lupus 19:1315–1325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Levy DM, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed A, Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators (2009) Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 60:1496–1507

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans GW, Yow E, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, Levy D, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy DK, Klein-Gitelman M, Wallace C, Silver RM, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Thompson SD, APPLE investigators (2014) Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis 73:557–566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Boros CA, Bradley TJ, Cheung MMH, Bargman JM, Russell JL, McCrindle BW, Adeli K, Hamilton J, Silverman ED (2011) Early determinants of atherosclerosis in paediatric systemic lupus erythematosus. Clin Exp Rheumatol 29:575–581

    CAS  PubMed  Google Scholar 

  28. Sozeri B, Deveci M, Dincel N, Mir S (2013) The early cardiovascular changes in pediatric patients with systemic lupus erythematosus. Pediatr Nephrol 28:471–476

    Article  PubMed  Google Scholar 

  29. El Gamal YM, Elmasry OAE, El Hadidi IS, Soliman OK (2013) Proximal aortic stiffness is increased in systemic lupus erythematosus activity in children and adolescents. ISRN Pediatr 2013:765253–5

    Article  PubMed  PubMed Central  Google Scholar 

  30. Quinlan C, Kari J, Pilkington C, Deanfield J, Shroff R, Marks SD, Tullus K (2015) The vascular phenotype of children with systemic lupus erythematosus. Pediatr Nephrol 30:1307–1316

  31. Kaplan MJ (2009) Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? Transl Res 154:61–69

    Article  CAS  PubMed  Google Scholar 

  32. Elshal M, Abdelaziz A, Abbas A, Mahmoud K, Fathy H, Mongy SE, El-Basyuoni S, Ahmed H, Mccoy P (2009) Quantification of circulating endothelial cells in peripheral blood of systemic lupus erythematosus patients: a simple and reproducible method of assessing endothelial injury and repair. Nephrol Dial Transplant 24:1495–1499

    Article  CAS  PubMed  Google Scholar 

  33. Speer MY, Yang H-Y, Brabb T, Leaf E, Look A, Lin W-L, Frutkin A, Dichek D, Giachelli CM (2009) Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 104:733–741

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pinho MM, Faria-Almeida R, Azevedo E, Manso MC, Martins L (2013) Periodontitis and atherosclerosis: an observational study. J Periodontal Res 48:452–457

    Article  PubMed  Google Scholar 

  35. Ravnskov U, McCully KS (2012) Infections may be causal in the pathogenesis of atherosclerosis. Am J Med Sci 344:391–394

    Article  PubMed  Google Scholar 

  36. Gkaliagkousi E, Gavriilaki E, Doumas M, Petidis K, Aslanidis S, Stella D (2012) Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. J Clin Rheumatol 18:422–430

    Article  PubMed  Google Scholar 

  37. Wong BW, Meredith A, Lin D, McManus BM (2012) The biological role of inflammation in atherosclerosis. Can J Cardiol 28:631–641

    Article  PubMed  Google Scholar 

  38. Gimbrone MA, Garcia-Cardena G (2013) Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol 22:9–15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hahn C, Schwartz MA (2009) Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol 10:53–62

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Korenaga R, Ando J, Kosaki K, Isshiki M, Takada Y, Kamiya A (1997) Negative transcriptional regulation of the VCAM-1 gene by fluid shear stress in murine endothelial cells. Am J Physiol 273:C1506–15

    CAS  PubMed  Google Scholar 

  41. Ando J, Tsuboi H, Korenaga R, Takahashi K, Kosaki K, Isshiki M, Tojo T, Takada Y, Kamiya A (1996) Differential display and cloning of shear stress-responsive messenger RNAs in human endothelial cells. Biochem Biophys Res Commun 225:347–351

    Article  CAS  PubMed  Google Scholar 

  42. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CFJ, Gimbron MAJ (1993) Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci U S A 90:7908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association (2004) Long-term survival of children with end-stage renal disease. N Engl J Med 350:2654–2662

    Article  Google Scholar 

  44. Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, Wolff ED, Davin JC, Heymans HSA (2002) Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int 61:621–629

    Article  PubMed  Google Scholar 

  45. Zhu D, Mackenzie NCW, Shanahan CM, Shroff RC, Farquharson C, MacRae VE (2014) BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth muscle cells through an ALK1-mediated pathway. J Cell Mol Med 19:165–174

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM (2010) Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 21:103–112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Shroff RC, Shanahan CM (2007) Vascular calcification in patients with kidney disease: the vascular biology of calcification. Semin Dial 20:103–109

    Article  PubMed  Google Scholar 

  48. Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D, Ellins EA, Storry C, Ridout D, Deanfield J, Rees L (2007) Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 18:2996–3003

    Article  CAS  PubMed  Google Scholar 

  49. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L (2008) The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23:3263–3271

    Article  CAS  PubMed  Google Scholar 

  50. Shroff R, Quinlan C, Mitsnefes M (2011) Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation? Pediatr Nephrol 26:853–865

    Article  PubMed  Google Scholar 

  51. Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2005) Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 16:2796–2803

    Article  CAS  PubMed  Google Scholar 

  52. Kranenburg AR, de Boer WI, Alagappan VKT, Sterk PJ, Sharma HS (2005) Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax 60:106–113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Querfeld U, Anarat A, Bayazit AK, Bakkaloglu AS, Bilginer Y, Caliskan S, Civilibal M, Doyon A, Duzova A, Kracht D, Litwin M, Melk A, Mir S, Sozeri B, Shroff R, Zeller R, Wühl E, Schaefer F, 4C Study Group (2010) The cardiovascular comorbidity in children with chronic kidney disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 5:1642–1648

    Article  PubMed  PubMed Central  Google Scholar 

  54. Santos MJ, Vinagre F, Silva JJ, Gil V, Fonseca JE (2010) Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of female patients. Acta Reumatol Port 35:325–332

    PubMed  Google Scholar 

  55. Kiani AN, Post WS, Magder LS, Petri M (2011) Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology 50:2071–2079

    Article  PubMed  PubMed Central  Google Scholar 

  56. Sabio JM, Vargas-Hitos JA, Mediavilla JD, Navarrete-Navarrete N, Zamora-Posadas M, Perez-Vicente S, Hidalgo-Tenorio C, Diaz-Chamorro A, Jaimez L, Jimenez-Alonso J, Grupo Lupus Virgen de las Nieves (2010) Correlation of asymptomatic hyperuricaemia and serum uric acid levels with arterial stiffness in women with systemic lupus erythematosus without clinically evident atherosclerotic cardiovascular disease. Lupus 19:591–598

    Article  CAS  PubMed  Google Scholar 

  57. Sabio JA, Vargas-Hitos JA, Mario J (2010) Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus: comments on the article by Mok et al. Scand J Rheumatol 39:527, author reply 527

    Article  CAS  PubMed  Google Scholar 

  58. Sabio JM, Zamora-Pasadas M, Jimenez-Jaimez J, Albadalejo F, Vargas-Hitos J, Rodriguez del Aguila MDM, Hidalgo-Tenorio C, Gonzalez-Gay MA, Jimenez-Alonso J (2008) Metabolic syndrome in patients with systemic lupus erythematosus from southern Spain. Lupus 17:849–859

    Article  CAS  PubMed  Google Scholar 

  59. Sabio JM, Vargas-Hitos JA, Navarrete-Navarrete N, Mediavilla JD, Jimenez-Jaimez J, Diaz-Chamorro A, Jimenez-Alonso J (2011) Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol 38:1026–1032

    Article  PubMed  Google Scholar 

  60. Sabio JM, Mediavilla JD, Fernandez-Torres C, Aliaga L, Jimenez-Alonso J (2001) Risk factors related to hypertension in a Spanish systemic lupus erythematosus cohort. Lupus 10:451–452

    Article  CAS  PubMed  Google Scholar 

  61. Rhew EY, Manzi SM, Dyer AR, Kao AH, Danchenko N, Barinas-Mitchell E, Sutton-Tyrrell K, McPherson DD, Pearce W, Edmundowicz D, Kondos GT, Ramsey-Goldman R (2009) Differences in subclinical cardiovascular disease between African American and Caucasian women with systemic lupus erythematosus. Transl Res 153:51–59

    Article  PubMed  PubMed Central  Google Scholar 

  62. Ghosh P, Kumar A, Kumar S, Aggarwal A, Sinha N, Misra R (2009) Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol 28:1259–1265

    Article  PubMed  Google Scholar 

  63. Alonso MD, Martínez-Vázquez F, Riancho-Zarrabeitia L, Díaz de Terán T, Miranda-Filloy JA, Blanco R, Gonzalez-Juanatey C, Llorca J, Gonzalez-Gay MA (2014) Sex differences in patients with systemic lupus erythematosus from Northwest Spain. Rheumatol Int 34:11–24

    Article  PubMed  Google Scholar 

  64. Olazagasti JM (2014) Critique and appraisal of a study on sex disparities in systemic lupus erythematosus. Rheumatol Int 34:1179–1180

    Article  PubMed  Google Scholar 

  65. Ding Y, He J, Guo J-P, Dai Y-J, Li C, Feng M, Li R, Li Z-G (2012) Gender differences are associated with the clinical features of systemic lupus erythematosus. Chin Med J 125:2477–2481

    PubMed  Google Scholar 

  66. Sekigawa I, Fujishiro M, Yamaguchi A, Kawasaki M, Inui A, Nozawa K, Takasaki Y, Takamori K, Ogawa H (2010) A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. Clin Exp Rheumatol 28:419–423

    PubMed  Google Scholar 

  67. Young NA, Wu L-C, Burd CJ, Friedman AK, Kaffenberger BH, Rajaram MVS, Schlesinger LS, James H, Shupnik MA, Jarjour WN (2014) Estrogen modulation of endosome-associated Toll-like receptor 8: an IFNα-independent mechanism of sex-bias in systemic lupus erythematosus. Clin Immunol 151:66–77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hsu C-Y, Chiu W-C, Yang T-S, Chen C-J, Chen Y-C, Lai H-M, Yu S-F, Su Y-J, Cheng T-T (2011) Age- and gender-related long-term renal outcome in patients with lupus nephritis. Lupus 20:1135–1141

    Article  PubMed  Google Scholar 

  69. de Carvalho JF, do Nascimento AP, Testagrossa LA, Barros RT, Bonfa E (2010) Male gender results in more severe lupus nephritis. Rheumatol Int 30:1311–1315

    Article  PubMed  Google Scholar 

  70. Wang Y-F, Xu Y-X, Tan Y, Yu F, Zhao M-H (2012) Clinicopathological characteristics and outcomes of male lupus nephritis in China. Lupus 21:1472–1481

    Article  PubMed  Google Scholar 

  71. de Leeuw K, Smit AJ, de Groot E, van Roon AM, Kallenberg CG, Bijl M (2009) Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis 206:546–550

    Article  PubMed  CAS  Google Scholar 

  72. Johnson HM, Douglas PS, Srinivasan SR, Bond MG, Tang R, Li S, Chen W, Berenson GS, Stein JH (2007) Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke 38:900–905

    Article  PubMed  Google Scholar 

  73. Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, Criswell LA (2011) Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res 63:261–268

    Article  Google Scholar 

  74. Sazliyana S, Mohd Shahrir MS, Kong NCT, Tan HJ, Hamidon BB, Azmi MT (2011) Thickened carotid intima media thickness and carotid atherosclerosis among lupus nephritis patients: the role of traditional and lupus-specific factors. Int J Rheum Dis 14:267–275

    Article  PubMed  Google Scholar 

  75. Yildiz M, Yildiz BS, Soy M, Tutkan H (2008) Impairment of arterial distensibility in premenopausal women with systemic lupus erythematosus. Kardiol Pol 66:1194–9, discussion 1200–1

    PubMed  Google Scholar 

  76. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, Fitzgerald J, Ragavendra N, Charles-Schoeman C, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH, McMahon M (2010) Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res 62:258–265

    Article  Google Scholar 

  77. Balsamo S, Santos-Neto LD (2011) Fatigue in systemic lupus erythematosus: an association with reduced physical fitness. Autoimmun Rev 10:514–518

    Article  PubMed  Google Scholar 

  78. Katz P, Julian L, Tonner MC, Yazdany J, Trupin L, Yelin E, Criswell LA (2012) Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. Arthritis Care Res 64:502–510

    Article  Google Scholar 

  79. Brooks D, Solway S, Gibbons WJ (2003) ATS statement on six-minute walk test. Am J Respir Crit Care Med 67:1287–1287

    Article  Google Scholar 

  80. Balsamo S, Nascimento DDC, Tibana RA, de Santana FS, da Mota LMH, Dos Santos-Neto LL (2013) The quality of life of patients with lupus erythematosus influences cardiovascular capacity in 6-minute walk test. Rev Bras Reumatol 53:75–87

    Article  PubMed  Google Scholar 

  81. Balsamo S, da Mota LMH, de Carvalho JF, Nascimento DDC, Tibana RA, de Santana FS, Moreno RL, Gualano B, dos Santos-Neto L (2013) Low dynamic muscle strength and its associations with fatigue, functional performance, and quality of life in premenopausal patients with systemic lupus erythematosus and low disease activity: a case–control study. BMC Musculoskelet Disord 14:263

    Article  PubMed  PubMed Central  Google Scholar 

  82. Mancuso CA, Perna M, Sargent AB, Salmon JE (2011) Perceptions and measurements of physical activity in patients with systemic lupus erythematosus. Lupus 20:231–242

    Article  CAS  PubMed  Google Scholar 

  83. Barnes JN, Nualnim N, Sugawara J, Sommerlad SM, Renzi CP, Tanaka H (2010) Arterial stiffening, wave reflection, and inflammation in habitually exercising systemic lupus erythematosus patients. Am J Hypertens 24:1194–1200

    Article  CAS  Google Scholar 

  84. Barnes J, Nualnim N, Dhindsa M, Renzi C, Tanaka H (2014) Macro- and microvascular function in habitually exercising systemic lupus erythematosus patients. Scand J Rheumatol 43:209–216

    Article  CAS  PubMed  Google Scholar 

  85. Barnes JN, Tanaka H (2012) Cardiovascular benefits of habitual exercise in systemic lupus erythematosus: a review. Phys Sportsmed 40:43–48

    Article  PubMed  Google Scholar 

  86. Barnes JN, Nualnim N, Sugawara J, Sommerlad SM, Renzi CP, Tanaka H (2011) Arterial stiffening, wave reflection, and inflammation in habitually exercising systemic lupus erythematosus patients. Am J Hypertens 24:1194–1200

    Article  CAS  PubMed  Google Scholar 

  87. Krupp LB, LaRocca NG, Muir J, Steinberg AD (1990) A study of fatigue in systemic lupus erythematosus. J Rheumatol 17:1450–1452

    CAS  PubMed  Google Scholar 

  88. Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30:8–13

    Article  PubMed  Google Scholar 

  89. Grundy SM (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752

    Article  PubMed  Google Scholar 

  90. Mok C, Poon W, Lai J, Wong C, Chiu S, Lun S, Ko G, Lam C, Lam C (2010) Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol 39:42–49

    Article  CAS  PubMed  Google Scholar 

  91. Tso TK, Huang W-N (2009) Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus. Rheumatol Int 29:735–742

    Article  CAS  PubMed  Google Scholar 

  92. Parker B, Bruce IN (2010) The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin N Am 36:81–97, viii

    Article  Google Scholar 

  93. Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, Mediavilla JD, Navarrete N, Ramirez A, Hidalgo-Tenorio C, Jaimez L, Martin J, Jimenez-Alonso J, Grupo Lupus Virgen de las Nieves (2009) Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36:2204–2211

    Article  CAS  PubMed  Google Scholar 

  94. Parker B, Ahmad Y, Shelmerdine J, Edlin H, Yates AP, Teh LS, Bruce IN (2011) An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 20:1459–1465

    Article  CAS  PubMed  Google Scholar 

  95. Parker B, Urowitz MB, Gladman DD, Lunt M, Bae S-C, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcon GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley M-A, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN (2013) Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 72:1308–1314

    Article  PubMed  PubMed Central  Google Scholar 

  96. Wang H, Li T, Chen S, Gu Y, Ye S (2015) NETs mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheum. doi:10.1002/art.39296

    Google Scholar 

  97. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305

    Article  CAS  PubMed  Google Scholar 

  98. Sazliyana S, Mohd Shahrir MS, Kong CTN, Tan HJ, Hamidon BB, Azmi MT (2011) Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus 20:1260–1266

    Article  CAS  PubMed  Google Scholar 

  99. Kamen DL (2010) Vitamin D in lupus - new kid on the block? Bull NYU Hosp Jt Dis 68:218–222

    PubMed  PubMed Central  Google Scholar 

  100. Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier M-C (2010) Vitamin D and inflammation. Joint Bone Spine 77:552–557

    Article  CAS  PubMed  Google Scholar 

  101. Breslin LC, Magee PJ, Wallace JMW, McSorley EM (2011) An evaluation of vitamin D status in individuals with systemic lupus erythematosus. Proc Nutr Soc 70:399–407

    Article  CAS  PubMed  Google Scholar 

  102. Robinson AB, Thierry-Palmer M, Gibson KL, Rabinovich CE (2012) Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J Pediatr 160:297–302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C, Zabek J, Kontny E, Wozniacka A (2010) Prevalence of autoantibodies directed against 1,25(OH)2D3 in patients with systemic lupus erythematosus. Pol Merkur Lek 28:103–107

    CAS  Google Scholar 

  104. Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C, Zabek J, Kontny E, McCauliffe D, Wozniacka A (2012) Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters. Lupus 21:477–484

    Article  CAS  PubMed  Google Scholar 

  105. Wu PW, Rhew EY, Dyer AR, Dunlop DD, Langman CB, Price H, Sutton-Tyrrell K, McPherson DD, Edmundowicz D, Kondos GT, Ramsey-Goldman R (2009) 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum 61:1387–1395

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Mok CC, Birmingham DJ, Ho LY, Hebert LA, Rovin BH (2013) High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res 65:441–447

    Article  CAS  Google Scholar 

  107. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA (2008) Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19:1509–1519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, Manoukian R, Damore M, Fitzpatrick D, Haas K, Twomey B, Kiaei P, Ward S, Lacey DL, Martin D (2006) Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 79:431–442

    Article  CAS  PubMed  Google Scholar 

  109. Lozovoy M, Simão A, Morimoto H, Iryioda T, Panis C, Reiche E, Borelli S, Oliveira S, Cecchini R, Dichi I (2014) Hypertension is associated with serologically active disease in patients with systemic lupus erythematosus: role of increased Th1/Th2 ratio and oxidative stress. Scand J Rheumatol 43:59–62

    Article  CAS  PubMed  Google Scholar 

  110. Harrison DG, Vinh A, Lob H, Madhur MS (2010) Role of the adaptive immune system in hypertension. Curr Opin Pharmacol 10:203–207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Harrison DG, Marvar PJ, Titze JM (2012) Vascular inflammatory cells in hypertension. Front Physiol 3:128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204:2449–2460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Rodríguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chávez M, Herrera-Acosta J, Johnson RJ, Pons HA (2002) Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282:F191–201

    Article  PubMed  Google Scholar 

  114. Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, Genin A, Van Dyke AL, Nackos E, Chander A, Gehrie E, Cron RQ, Whitehead AS (2006) Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 54:2220–2227

    Article  CAS  Google Scholar 

  115. Von Feldt JM (2008) The cardiovascular threat of lupus. Nat Clin Pract Rheumatol 4:505

    Article  Google Scholar 

  116. Becker-Merok A, Nossent J (2009) Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. Lupus 18:508–515

    Article  CAS  PubMed  Google Scholar 

  117. Petri M, Orbai A-M, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae S-C, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley M-A, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G, Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686

    Article  PubMed  PubMed Central  Google Scholar 

  118. Petri M, Purvey S, Fang H, Magder LS (2012) Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64:4021–4028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Kis E, Cseprekál O, Kerti A, Salvi P, Benetos A, Tisler A, Szabó A, Tulassay T, Reusz GS (2011) Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices. Hypertens Res 34:1197–1202

    Article  PubMed  Google Scholar 

  120. Shroff R, Dégi A, Kerti A, Kis E, Cseprekál O, Tory K, Szabó AJ, Reusz GS (2013) Cardiovascular risk assessment in children with chronic kidney disease. Pediatr Nephrol 28:875–884

    Article  PubMed  Google Scholar 

  121. Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, Cockcroft J, Kaiser DR, Thuillez C (2002) Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens 15:445–452

    Article  PubMed  Google Scholar 

  122. Reusz GS, Cseprekál O, Temmar M, Kis E, Cherif AB, Thaleb A, Fekete A, Szabó AJ, Benetos A, Salvi P (2010) Reference values of pulse wave velocity in healthy children and teenagers. Hypertension 56:217–224

    Article  CAS  PubMed  Google Scholar 

  123. Kracht D, Shroff R, Baig S, Jacobi C, Zeller R, Querfeld U, Schaefer F, Wühl E, Schmidt BMW, Melk A, 4C Study Consortium (2011) Validating a new oscillometric device for aortic pulse wave velocity measurements in children and adolescents. Am J Hypertens 24:1294–1299

    Article  PubMed  Google Scholar 

  124. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE (2007) Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 56:3412–3419

    Article  CAS  PubMed  Google Scholar 

  125. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents (2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl 5):S213–S256

    Article  PubMed Central  Google Scholar 

  126. Ainsworth BE, Macera CA, Jones DA, Reis JP, Addy CL, Bowles HR, Kohl HW (2006) Comparison of the 2001 BRFSS and the IPAQ physical activity questionnaires. Med Sci Sports Exerc 38:1584–1592

    Article  PubMed  Google Scholar 

  127. Ainsworth BE, Bassett DR, Strath SJ, Swartz AM, O’Brien WL, Thompson RW, Jones DA, Macera CA, Kimsey CD (2000) Comparison of three methods for measuring the time spent in physical activity. Med Sci Sports Exerc 32:S457–S464

    Article  CAS  PubMed  Google Scholar 

  128. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395

    Article  PubMed  Google Scholar 

  129. Azevedo MR, Araújo CL, Cozzensa da Silva M, Hallal PC (2007) Tracking of physical activity from adolescence to adulthood: a population-based study. Rev Saude Publica 41:69–75

    Article  PubMed  Google Scholar 

  130. Fogelholm M, Malmberg J, Suni J, Santtila M, Kyröläinen H, Mäntysaari M, Oja P (2006) International physical activity questionnaire: validity against fitness. Med Sci Sports Exerc 38:753–760

    Article  PubMed  Google Scholar 

  131. Hagströmer M, Oja P, Sjöström M (2006) The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr 9:755–762

    Article  PubMed  Google Scholar 

  132. Katano S, Nakamura Y, Nakamura A, Murakami Y, Tanaka T, Nakagawa H, Takebayashi T, Yamato H, Okayama A, Miura K, Okamura T, Ueshima H, HIPOP-OHP Research Group (2010) Relationship among physical activity, smoking, drinking and clustering of the metabolic syndrome diagnostic components. J Atheroscler Thromb 17:644–650

    Article  PubMed  Google Scholar 

  133. Rua-Figueroa I, Arencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, Francisco F, Naranjo A, Rodríguez-Gallego C, Garcia-Laorden I, Rodríguez-Perez J, Rodríguez-Lozano C (2010) Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 69:1136–1139

    Article  CAS  PubMed  Google Scholar 

  134. Hunt BJ (2008) Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 34:274–281

    Article  CAS  PubMed  Google Scholar 

  135. Avcin T, Cimaz R, Rozman B, Ped-APS Registry Collaborative Group (2009) The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus 18:894–899

    Article  Google Scholar 

  136. Ahluwalia J, Singh S, Naseem S, Suri D, Rawat A, Gupta A, Masih J, Bose S (2014) Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India. Rheumatol Int 34:669–673

    Article  CAS  PubMed  Google Scholar 

  137. Lambrianides A, Carroll CJ, Pierangeli SS, Pericleous C, Branch W, Rice J, Latchman DS, Townsend P, Isenberg DA, Rahman A, Giles IP (2010) Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 184:6622–6628

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Charakida M, Jones A, Falaschetti E, Khan T, Finer N, Sattar N, Hingorani A, Lawlor DA, Smith GD, Deanfield JE (2012) Childhood obesity and vascular phenotypes: a population study. J Am Coll Cardiol 60:2643–2650

    Article  PubMed  Google Scholar 

  139. Ames PRJ, Batuca JR, Ciampa A, Iannaccone L, Delgado Alves J (2010) Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome. J Rheumatol 37:2523–2530

    Article  CAS  PubMed  Google Scholar 

  140. Dal Ben ERR, do Prado CH, Baptista TSA, Bauer ME, Staub HL (2014) Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4+CD25+Foxp3+ Treg and CD3−CD19+ B cells. Rev Bras Reumatol 54:241–246

    Article  PubMed  Google Scholar 

  141. Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, Wang G, Tousoulis D, Delgado Alves J, Loukogeorgakis SP, Mackworth-Young C, D’Cruz D, Luscher T, Landmesser U, Deanfield JE (2009) Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 302:1210

    Article  CAS  PubMed  Google Scholar 

  142. MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, Isenberg DA (1992) Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 51:152–155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997

    Article  CAS  PubMed  Google Scholar 

  144. Fonseca AG, D’Cruz DP (2008) Controversies in the antiphospholipid syndrome: can we ever stop warfarin? J Autoimmun Dis 5:6

    Article  CAS  Google Scholar 

  145. Ferrara DE, Liu X, Espinola RG, Meroni PL, Abukhalaf I, Harris EN, Pierangeli SS (2003) Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 48:3272–3279

    Article  CAS  PubMed  Google Scholar 

  146. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, Khamashta MA, Tremoli E, Camera M (2001) Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44:2870–2878

    Article  CAS  PubMed  Google Scholar 

  147. Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, Rodriguez-Ariza A, Cuadrado MJ (2012) Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep 14:87–94

    Article  CAS  PubMed  Google Scholar 

  148. Fangtham M, Petri M (2013) 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 15:360

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  149. Ioannou Y, Lambrianides A, Cambridge G, Leandro MJ, Edwards JCW, Isenberg DA (2008) B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 67:425–426

    Article  CAS  PubMed  Google Scholar 

  150. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60

    Article  CAS  PubMed  Google Scholar 

  151. Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Boutin DLTH, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacre K, Fain O, Stirnemann J, Cacoub P, Jallouli M, Leroux G, Cohen-Bittan J, Tanguy ML, Hulot JS, Lechat P, Musset L, Amoura Z, Piette JC, on behalf of Group PLUS, Astudillo L, Belizna C, Belmatoug N, Benveniste O, Benyamine A, Bezanahary H, Blanco P, Bletry O, Bodaghi B, Bourgeois P, Brihaye B, Chatelus E, Damade R, Daugas E, de-Gennes C, Delfraissy JF, Delluc C, Delluc A, Duhaut P, Dupuy A, Durieu I, Hang-Korng E, Farge D, Funck-Brentano C, Gandjbakhch F, Gellen-Dautremer J, Ghillani-Dalbin P, Godeau B, Goujard C, Grandpeix C, Grange C, Grimaldi L, Guettrot-Imbert G, Guillevin L, Hachulla E, Harle JR, Haroche J, Hausfater P, Jouquan J, Kaplanski G, Keshtmand H, Khellaf M, Lambotte O, Launay D, Levesque H, Lidove O, Liozon E, Kim L, Mahevas M, Mariampillai K, Mariette X, Mathian A, Mazodier K, Michel M, Morel N, Mouthon L, Ngack R, Ninet J, Oksenhendler E, Pellegrin JL, Peyr O, Piette AM, Poindron V, Roux F, Saadoun D, Sahali S, Saint-Marcoux B, Sarrot-Reynauld F, Schoindre Y, Sellam J, Sene D, Serratrice J, Seve P, Sibilia J, Simon C, Sordet C, Terrier B, Trad S, Viallard JF, Vidal E, Wechsler B, Weiller PJ, Zahr N (2013) Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 72:1786–1792

    Article  CAS  PubMed  Google Scholar 

  152. Sacre K, Criswell LA, McCune JM (2012) Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 14:R155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Tang C, Godfrey T, Stawell R, Nikpour M (2012) Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 42:968–978

    CAS  PubMed  Google Scholar 

  154. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J (1997) Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 3:3–8

    Article  CAS  PubMed  Google Scholar 

  155. Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D (2007) Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad Sci 1108:24–34

    Article  CAS  PubMed  Google Scholar 

  156. Cairoli E, Rebella M, Danese N, Garra V, Borba EF (2012) Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 21:1178–1182

    Article  CAS  PubMed  Google Scholar 

  157. Roldan CA, Joson J, Qualls CR, Sharrar J, Sibbitt WL (2010) Premature aortic stiffness in systemic lupus erythematosus by transesophageal echocardiography. Lupus 19:1599–1605

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G (2011) Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 6:2192–2199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Kallenberg CGM (2013) Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis? Ann Rheum Dis 72(Suppl 2):ii62–ii65

    CAS  PubMed  Google Scholar 

  160. Hogan J, Schwenk MH, Radhakrishnan J (2012) Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int 82:1256–1260

    Article  CAS  PubMed  Google Scholar 

  161. Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M (2009) Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. Transplant Proc 41:1175–1177

    Article  CAS  PubMed  Google Scholar 

  162. Yap DYH, Ma MKM, Tang CS, Chan TM (2012) Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology (Carlton) 17:676–680

    Article  CAS  Google Scholar 

  163. van Leuven SI, van Wijk DF, Volger OL, de Vries J-PPM, van der Loos CM, de Kleijn DVP, Horrevoets AJG, Tak PP, van der Wal AC, de Boer OJ, Pasterkamp G, Hayden MR, Kastelein JJP, Stroes ES (2010) Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 211:231–236

    Article  PubMed  CAS  Google Scholar 

  164. Richez C, Richards RJ, Duffau P, Weitzner Z, Andry CD, Rifkin IR, Aprahamian T (2013) The effect of mycophenolate mofetil on disease development in the gld.apoE (−/−) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. PLoS ONE 8, e61042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Witztum JL, Lichtman AH (2014) The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol 9:73–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, Figueiredo J-L, Iwamoto Y, Theurl I, Gorbatov R, Waring MT, Chicoine AT, Mouded M, Pittet MJ, Nahrendorf M, Weissleder R, Swirski FK (2012) Innate response activator B cells protect against microbial sepsis. Science 335:597–601

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Shaposhnik Z, Wang X, Weinstein M, Bennett BJ, Lusis AJ (2007) Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 27:621–627

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Haghighat A, Weiss D, Whalin MK, Cowan DP, Taylor WR (2007) Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation 115:2049–2054

    Article  CAS  PubMed  Google Scholar 

  169. Tullus K, Marks SD (2013) Indications for use and safety of rituximab in childhood renal diseases. Pediatr Nephrol 28:1001–1009

    Article  PubMed  Google Scholar 

  170. Weidenbusch M, Römmele C, Schröttle A, Anders H-J (2013) Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 28:106–111

    Article  CAS  PubMed  Google Scholar 

  171. Specker C (2013) The LUNAR study: rituximab for lupus nephritis? Z Rheumatol 72:300–302

    Article  CAS  PubMed  Google Scholar 

  172. Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh H-J, Brunetta P (2011) Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20:709–716

    Article  CAS  PubMed  Google Scholar 

  173. Thacker SG, Duquaine D, Park J, Kaplan MJ (2010) Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 19:288–299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Mosak J, Furie R (2013) Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy. Lupus 22:361–371

    Article  CAS  PubMed  Google Scholar 

  175. Mathieu S, Pereira B, Dubost J-J, Lusson J-R, Soubrier M (2012) No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology 51:1107–1111

    Article  CAS  PubMed  Google Scholar 

  176. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:1821–1824

    Article  CAS  PubMed  Google Scholar 

  177. Pego-Reigosa JM, Lu TY-T, Fontanillo MF, del Campo-Perez V, Rahman A, Isenberg DA (2010) Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology 49:691–696

    Article  CAS  PubMed  Google Scholar 

  178. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1, CD004816

    PubMed  Google Scholar 

  179. Waehre T (2004) Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 109:1966–1972

    Article  CAS  PubMed  Google Scholar 

  180. Ravelli A (2012) Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis? Arthritis Rheum 64:33–36

    Article  PubMed  Google Scholar 

  181. van Leuven SI, Mendez-Fernandez YV, Stroes ES, Tak PP, Major AS (2011) Statin therapy in lupus-mediated atherogenesis: two birds with one stone? Ann Rheum Dis 70:245–248

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  182. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR (2004) Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 173:7641–7646

    Article  CAS  PubMed  Google Scholar 

  183. Woo JMP, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KMT, Li H, Castellani LW, Wang X, Iikuni N, Rullo OJ, Wu H, La Cava A, Fogelman AM, Lusis AJ, Tsao BP (2010) Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 12:R93

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  184. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS (2011) Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 70:760–765

    Article  CAS  PubMed  Google Scholar 

  185. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD (2012) Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 64:285–296

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Kirou KA, Kalliolias GD (2010) A new tool for detection of type I interferon activation in systemic lupus erythematosus. Arthritis Res Ther 12:138

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  187. Nikpour M, Urowitz M, Ibanez D, Gladman D (2011) Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus. Lupus 20:299–304

    Article  CAS  PubMed  Google Scholar 

  188. Plazak W, Pasowicz M, Kostkiewicz M, Podolec J, Tomkiewicz-Pajak L, Musial J, Podolec P (2011) Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res 60:973–980

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Petri M (2004) The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 114:593–595

    Article  CAS  PubMed  Google Scholar 

  190. Kümpers P, David S, Haubitz M, Hellpap J, Horn R, Bröcker V, Schiffer M, Haller H, Witte T (2009) The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis 68:1638–1643

    Article  PubMed  CAS  Google Scholar 

  191. Zardi EM, Afeltra A (2010) Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: are they early markers of subclinical atherosclerosis? Autoimmun Rev 9:684–686

    Article  CAS  PubMed  Google Scholar 

  192. Kluz J, Kopeć W, Jakobsche-Policht U, Adamiec R (2009) Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis. Int Angiol 28:192–201

    CAS  PubMed  Google Scholar 

  193. Zhao W, Thacker SG, Hodgin JB, Zhang H, Wang JH, Park JL, Randolph A, Somers EC, Pennathur S, Kretzler M, Brosius FC, Kaplan MJ (2009) The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol 183:2729–2740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Ebner P, Picard F, Richter J, Darrelmann E, Schneider M, Strauer B-E, Brehm M (2010) Accumulation of VEGFR-2+/CD133+ cells and decreased number and impaired functionality of CD34+/VEGFR-2+ cells in patients with SLE. Rheumatology 49:63–72

    Article  CAS  PubMed  Google Scholar 

  195. Braun NA, Wade NS, Wakeland EK, Major AS (2008) Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(−/−) mice. Lupus 17:1070–1078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S (2005) Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288:H2031–H2041

    Article  CAS  PubMed  Google Scholar 

  197. Vadacca M, Margiotta D, Rigon A, Cacciapaglia F, Coppolino G, Amoroso A, Afeltra A (2009) Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 36:295–297

    Article  CAS  PubMed  Google Scholar 

  198. Krysiak R, Handzlik-Orlik G, Okopien B (2012) The role of adipokines in connective tissue diseases. Eur J Nutr 51:513–528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Vadacca M, Zardi EM, Margiotta D, Rigon A, Cacciapaglia F, Arcarese L, Buzzulini F, Amoroso A, Afeltra A (2013) Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus. Intern Emerg Med 8:705–712

    Article  PubMed  Google Scholar 

  200. Vadacca M, Margiotta DPE, Navarini L, Afeltra A (2011) Leptin in immuno-rheumatological diseases. Cell Mol Immunol 8:203–212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Moroni G, Novembrino C, Quaglini S, De Giuseppe R, Gallelli B, Uva V, Montanari V, Messa P, Bamonti F (2010) Oxidative stress and homocysteine metabolism in patients with lupus nephritis. Lupus 19:65–72

    Article  CAS  PubMed  Google Scholar 

  202. Li L, Mamputu J-C, Wiernsperger N, Renier G (2005) Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin. Diabetes 54:2227–2234

    Article  CAS  PubMed  Google Scholar 

  203. McCullough PA, Agrawal V, Danielewicz E, Abela GS (2008) Accelerated atherosclerotic calcification and Monckeberg’s sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 3:1585–1598

    Article  CAS  PubMed  Google Scholar 

  204. Matarese G, Procaccini C, De Rosa V, Horvath TL, La Cava A (2010) Regulatory T cells in obesity: the leptin connection. Trends Mol Med 16:247–256

    Article  CAS  PubMed  Google Scholar 

  205. Procaccini C, De Rosa V, Galgani M, Carbone F, Cassano S, Greco D, Qian K, Auvinen P, Cali G, Stallone G, Formisano L, La Cava A, Matarese G (2012) Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J Immunol 189:2941–2953

    Article  CAS  PubMed  Google Scholar 

  206. Toussirot E, Gaugler B, Bouhaddi M, Nguyen NU, Saas P, Dumoulin G (2010) Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediat Inflamm 2010:938408

    Article  CAS  Google Scholar 

  207. McMahon M, Skaggs BJ, Sahakian L, Grossman J, Fitzgerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH (2011) High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 70:1619–1624

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Davies JD, Carpenter KLH, Challis IR, Figg NL, McNair R, Proudfoot D, Weissberg PL, Shanahan CM (2005) Adipocytic differentiation and liver x receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells. J Biol Chem 280:3911–3919

    Article  CAS  PubMed  Google Scholar 

  209. Kahlenberg JM, Kaplan MJ (2011) The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther 13:203

    Article  PubMed  PubMed Central  Google Scholar 

  210. Keicho N, Matsushita I, Tanaka T, Shimbo T, Hang NTL, Sakurada S, Kobayashi N, Hijikata M, Thuong PH, Lien LT (2012) Circulating levels of adiponectin, leptin, fetuin-A and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation. PLoS ONE 7, e38703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  211. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451

    Article  CAS  PubMed  Google Scholar 

  212. Wilk S, Scheibenbogen C, Bauer S, Jenke A, Rother M, Guerreiro M, Kudernatsch R, Goerner N, Poller W, Elligsen-Merkel D, Utku N, Magrane J, Volk HD, Skurk C (2011) Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol 41:2323–2332

    Article  CAS  PubMed  Google Scholar 

  213. Okamoto Y, Christen T, Shimizu K, Asano K, Kihara S, Mitchell RN, Libby P (2009) Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 88:879–883

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P (2008) Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 102:218–225

    Article  CAS  PubMed  Google Scholar 

  215. Tsang JYS, Li D, Ho D, Peng J, Xu A, Lamb J, Chen Y, Tam PKH (2011) Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunopharmacol 11:604–609

    Article  CAS  PubMed  Google Scholar 

  216. Jung MY, Kim H-S, Hong H-J, Youn B-S, Kim TS (2012) Adiponectin induces dendritic cell activation via PLCγ/JNK/NF-κB pathways, leading to Th1 and Th17 polarization. J Immunol 188:2592–2601

    Article  CAS  PubMed  Google Scholar 

  217. Kim K-Y, Kim JK, Han SH, Lim J-S, Kim KI, Cho DH, Lee M-S, Lee J-H, Yoon D-Y, Yoon SR, Chung JW, Choi I, Kim E, Yang Y (2006) Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol 176:5958–5964

    Article  CAS  PubMed  Google Scholar 

  218. Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukumoto S, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2005) Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 54:330–334

    Article  CAS  PubMed  Google Scholar 

  219. D’Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, Di Benedetto A (2006) Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG 113:1264–1269

    Article  PubMed  CAS  Google Scholar 

  220. Haugen F, Drevon CA (2007) Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 148:5478–5486

    Article  CAS  PubMed  Google Scholar 

  221. Heinrichsdorff J, Olefsky JM (2012) Fetuin-A: the missing link in lipid-induced inflammation. Nat Med 18:1182–1183

    Article  CAS  PubMed  Google Scholar 

  222. Yuce M, Davutoglu V, Cakici M (2010) Fetuin-A, osteoporosis and inflammation--proposal of possible mechanisms for vascular and valvular calcification in chronic kidney disease. Nephrol Dial Transplant 25:2801, author reply 2801–2

    Article  CAS  PubMed  Google Scholar 

  223. Komaba H, Fukagawa M (2009) Fetuin-mineral complex: a new potential biomarker for vascular calcification? Kidney Int 75:874–876

    Article  CAS  PubMed  Google Scholar 

  224. Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y (2010) Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism 59:873–878

    Article  CAS  PubMed  Google Scholar 

  225. Westenfeld R, Schäfer C, Krüger T, Haarmann C, Schurgers LJ, Reutelingsperger C, Ivanovski O, Drueke T, Massy ZA, Ketteler M, Floege J, Jahnen-Dechent W (2009) Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 20:1264–1274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  226. Shanahan CM (2005) Vascular calcification. Curr Opin Nephrol Hypertens 14:361–367

    Article  CAS  PubMed  Google Scholar 

  227. Ix JH, Sharma K (2010) Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-a, adiponectin, and AMPK. J Am Soc Nephrol 21:406–412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  228. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S (2005) Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 67:1070–1077

    Article  CAS  PubMed  Google Scholar 

  229. Liu B, Yang Y, Dai J, Medzhitov R, Freudenberg MA, Zhang PL, Li Z (2006) TLR4 Up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 177:6880–6888

    Article  CAS  PubMed  Google Scholar 

  230. Lartigue A, Colliou N, Calbo S, François A, Jacquot S, Arnoult C, Tron F, Gilbert D, Musette P (2009) Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol 183:6207–6216

    Article  CAS  PubMed  Google Scholar 

  231. Li Y, Lee PY, Kellner ES, Paulus M, Switanek J, Xu Y, Zhuang H, Sobel ES, Segal MS, Satoh M, Reeves WH (2010) Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 12:R90

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  232. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A, Rabquer BJ, Koch AE, Pennathur S, Davidson A, Eitzman DT, Kaplan MJ (2012) Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 64:2975–2985

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  233. Zhu S, Liu X, Li Y, Goldschmidt-Clermont PJ, Dong C (2007) Aging in the atherosclerosis milieu may accelerate the consumption of bone marrow endothelial progenitor cells. Arterioscler Thromb Vasc Biol 27:113–119

    Article  PubMed  CAS  Google Scholar 

  234. Lood C, Amisten S, Gullstrand B, Jonsen A, Allhorn M, Truedsson L, Sturfelt G, Erlinge D, Bengtsson AA (2010) Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 116:1951–1957

    Article  CAS  PubMed  Google Scholar 

  235. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K (2003) Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9:61–67

    Article  CAS  PubMed  Google Scholar 

  236. Li J, Fu Q, Cui H, Qu B, Pan W, Shen N, Bao C (2011) Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. Arthritis Rheum 63:492–502

    Article  CAS  PubMed  Google Scholar 

  237. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM (2007) Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 116:2043–2052

    Article  CAS  PubMed  Google Scholar 

  238. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, Kazerooni EA, McCune WJ, Kaplan MJ (2010) Type I interferons Are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE 7, e37000

    Article  CAS  Google Scholar 

  239. Taleb S, Van Haaften R, Henegar C, Hukshorn C, Cancello R, Pelloux V, Hanczar B, Viguerie N, Langin D, Evelo C, Zucker J, Clément K, Saris WHM (2006) Microarray profiling of human white adipose tissue after exogenous leptin injection. Eur J Clin Invest 36:153–163

    Article  CAS  PubMed  Google Scholar 

  240. Singh IM, Shishehbor MH, Ansell BJ (2007) High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298:786–798

    Article  CAS  PubMed  Google Scholar 

  241. Amarenco P, Labreuche J, Touboul P-J (2008) High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 196:489–496

    Article  CAS  PubMed  Google Scholar 

  242. Mureddu GF, Brandimarte F, De Luca L (2012) High-density lipoprotein levels and risk of cardiovascular events: a review. J Cardiovasc Med (Hagerstown) 13:575–586

    Article  CAS  Google Scholar 

  243. Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410–1422

    Article  CAS  PubMed  Google Scholar 

  244. Norata GD, Pirillo A, Ammirati E, Catapano AL (2012) Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 220:11–21

    Article  CAS  PubMed  Google Scholar 

  245. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM (2009) HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 58:2711–2717

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  246. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, Farias-Eisner R, Fogelman AM, Reddy ST (2011) Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J 75:1533–1538

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Kavey R-EW, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J, American Heart Association Expert Panel on Population and Prevention Science, American Heart Association Council on Cardiovascular Disease in the Young, American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Nutrition Physical Activity and Metabolism, American Heart Association Council on High Blood Pressure Research, American Heart Association Council on Cardiovascular Nursing, American Heart Association Council on the Kidney in Heart Disease, Interdisciplinary Working Group on Quality of Care and Outcomes Research (2006) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114:2710–2738

    Article  PubMed  Google Scholar 

  248. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, SCORE project group (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003

    Article  CAS  PubMed  Google Scholar 

  249. O’Neill SG, Pego-Reigosa JM, Hingorani AD, Bessant R, Isenberg DA, Rahman A (2009) Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 48:573–575

    Article  PubMed  Google Scholar 

  250. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH (2009) Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 60:2428–2437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  251. Navab M, Reddy ST, Van Lenten BJ, Buga GM, Hough G, Wagner AC, Fogelman AM (2012) High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol 32:2553–2560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  252. Mok CC, Wong CK, To CH, Lai JPS, Lam CS (2011) Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 63:875–883

    Article  CAS  Google Scholar 

  253. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M (2012) Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51:314–324

    Article  CAS  PubMed  Google Scholar 

  254. Ragbir S, Farmer JA (2010) Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 12:343–348

    Article  CAS  PubMed  Google Scholar 

  255. Sala F, Catapano AL, Norata GD (2012) High density lipoproteins and atherosclerosis: emerging aspects. J Geriatr Cardiol 9:401–407

    CAS  PubMed  PubMed Central  Google Scholar 

  256. Vivekanandan-Giri A, Slocum JL, Byun J, Tang C, Sands RL, Gillespie BW, Heinecke JW, Saran R, Kaplan MJ, Pennathur S (2013) High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis 72:1735–1731

    Article  CAS  Google Scholar 

  257. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83:503–508

    Article  CAS  PubMed  Google Scholar 

  258. Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863

    Article  CAS  PubMed  Google Scholar 

  259. Borba EF, Bonfa E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539

    Article  CAS  PubMed  Google Scholar 

  260. Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M (2010) Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production. Clin Immunol 137:147–156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Nephrology, The Royal Children’s Hospital, Parkville, VIC, 3052, Australia

    Catherine Quinlan

  2. Great Ormond Street Hospital for Children NHS Trust, London, UK

    Stephen D. Marks & Kjell Tullus

Authors
  1. Catherine Quinlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen D. Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kjell Tullus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Quinlan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quinlan, C., Marks, S.D. & Tullus, K. Why are kids with lupus at an increased risk of cardiovascular disease?. Pediatr Nephrol 31, 861–883 (2016). https://doi.org/10.1007/s00467-015-3202-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-015-3202-7

Keywords

Search

Navigation